China Biopharmaceutical Industry Report, 2005-2006
  • Oct/2005
  • Hard Copy
  • USD $1,100
  • Pages:81
  • Single User License
    (PDF Unprintable)       
  • USD $1,200
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,800
  • Hard Copy + Single User License
  • USD $1,300

The report is classified into five parts, as follows:

1. Macro information on China's biopharmaceutical industry

China's macroeconomic environment analysis; China's policies and regulations on biopharmaceutical industry; China's access to WTO and its influence on China's biopharmaceutical industry; biopharmaceutical industrial technology level, developing situation and trends at home and abroad.

2. The global biopharmaceutical market

Current R&D trends of the global biopharmaceutical industry; global biopharmaceutical market analysis before and in 2005, including: market scale, sales status, products and enterprises analysis.

3. In-depth perspectives on China's biopharmaceutical industry and market

Quantitative and qualitative analysis of China's biopharmaceutical production and market sales characteristics before and in 2005; problems existing in China's biopharmaceutical industry; analysis on biological engineering, biological vaccine, diagnosis reagent and IFN markets; the status of China's biopharmaceutical operations;

4. Biotechnology development and market trends

The latest development trends and advanced management systems. Market forecast on China's biopharmaceutical market in 2006, including: factors influencing China's biopharmaceutical industry development in 2006, China's biopharmaceutical market variables in 2006, and future development of China's biopharmaceutical industry. 

5. Investment suggestions

Investment feasibility analysis, risk analysis, profitability analysis and products development suggestions.


1.Macro environment of China's biopharmaceutical industry in 2005 
1.1 Social and economy development
1.1.1 China national economy analysis and forecast, 2005-2006 
1.1.2 China's pharmaceutical operations in 2005
1.2 Population environment analysis
1.2.1 Demography over past years
1.2.2 Population aging and its influences
1.2.3 Residents' income and consumption
1.2.4 Residents' disease spectrum and medical consumption changes
1.3 Residents' medical consumption structure 
1.3.1 Chinese urban and rural medical consumption structure
1.3.2 Per capita medical treatment expenses and variables 

2.The political environment of Chin's biopharmaceutical industry in 2006
2.1 China's medical regulatory system analysis
2.1.1 Government control on medical industry 
2.1.2 Establishment of the national medical system
2.1.3 GMP certification
2.1.4 GSP certification for drug enterprises
2.1.5 GAP certification for Chinese traditional medicine 
2.1.6 GCP police for new drug experiments
2.1.7 International GLP accreditation advanced in China
2.1.8 MOH's administrative and regulatory measures to medical industry in 2005 
2.2 China's medical treatment system reform and its influences
2.2.1 Basic urban medical insurance system  
2.2.2 Rural medical treatment system improvements
2.2.3 Commercial medical insurance system establishment and its influences 
2.4 Medicine intellectual property right protections
2.4.1 Fake and patent drugs
2.4.2 WTO related clauses 
2.4.3 The intellectual property right protection of Chinese traditional medicine 
2.5 Medical open-up policy after China's access to WTO
2.5.1 Commitments on medical products after China's access to WTO 
2.5.2 Related policies for foreign investments in medical manufacturing 

3.Technological environment analysis of China's biopharmaceutical industry in 2006
3.1 The global development of basic medical science in 2005 and perspectives on 2006
3.1.1 Global medical research and development in 2005
3.1.2 Analysis of failed cases on global medical research, 2004-2005
3.1.3 Global medical market hotspots forecast in 2006
3.1.4 WHO's 6 drug categories prior to be developed 
3.2 China's medical development
3.2.1 China's basic medical science development
3.2.2 Medical products development in china
3.2.3 Medicine certification in China, 2004-2005
3.2.4 New medical research hotspots in China in 2006

4.China's biopharmaceutical industry investment
4.1 Investment characteristics
4.1.1 Growth analysis 
4.1.2 Profitability analysis 
4.1.3 Investment barriers analysis 
4.1.4 Investment risk analysis 
4.2 Investments in China's Pharmaceuticals industry in 2005
4.2.1 New and under-process projects 
4.2.2 Investment fund sources and allocation 
4.2.3 Investment returns and existing problems 
4.3 Investment forecast in 2006
4.3.1 Investment scale forecast
4.3.2 Investment distribution forecast
4.3.3. Investment return forecast

5.The global biopharmaceutical market in 2005
5.1 The current biopharmaceutical R&D trends
5.2 Global biopharmaceutical industrial characteristics 

6.China's biopharmaceutical industry development

6.1 China's biopharmaceutical industry operations in 2005
6.1.1 Operation 
6.1.2 Market characteristics
6.2 Existing problems

7.Biopharmaceutical products analysis
7.1 Genetic engineering products
7.1.1 Genetic engineering application and medical innovations
7.1.2 Status quo of China’s genetic engineering products
7.1.3 R&D strength survey of China's genetic engineering enterprises
7.1.4 Genetic engineering prospects
7.2 Biological vaccine
7.2.1 China's vaccines market 
7.2.2 Vaccines market potentials
7.3 Biological diagnosis reagent
7.4 Interferon 

8.China's biopharmaceutical enterprises analysis
8.1 Enterprises rank
8.1.1 Sales of the top 10 biopharmaceutical enterprises in 2005
8.1.2 Sales of the top 200 Biopharmaceutical enterprises in 2004 according to NBSC
8.1.3 Profit of the top 200 Biopharmaceutical enterprises in 2004 according to NBSC
8.2 Operations of listed biopharmaceutical enterprises

9.Biological technology analysis
9.1 The development trends of the global biotechnology and industry
9.1.1 American biotechnology industry is reviving  
9.1.2 Constant growth of biopharmaceutical sales in the world
9.1.3 Continued plant area expansion of the transgenic crops 
9.1.4 Systematization and comprehension of biological technology 
9.1.5 Scientists succeeded in SARS breakthrough
9.2 Biotechnology research and industrialization 
9.2.1 America NIH 
9.2.2 Europe 
9.2.3 Japan
9.2.4 Other countries 
9.3 The latest Biotechnology developments

10.Market forecast on China's biopharmaceutical in 2006 
10.1 Analysis of factors influences China’s biopharmaceutical industry development
10.2 China's biopharmaceutical industry development in 2006 and next ten years
10.3 Perspectives on China's biopharmaceutical industry 
10.3.1 Opportunity brought by biopharmaceutical R&D 
10.3.2 Price down and medical market is thereby further expansive
10.3.3 Market forecast 
10.3.4 International trade 

11.Investment suggestion
11.1 Investment blanks
11.2 Investment orientation
Proportion of the global listed biopharmaceutical companies in 2004 
Pharmaceutical and genetic engineering medical market of America, Japan, German and China
Genetic engineering products with sale volume of US$1-3.5 billion in the world 
The sales scale of biopharmaceuticals products, 1996-2004 
Annual average growth rate of biopharmaceuticals products, 1996-2004
Biopharmaceutical products and vaccines launched from 1982 to 2002 
Biopharmaceutical products launched in America in 2004 
Sales statistics of genetic engineering products in Japan
Genetic engineering manufacturers in China
Three stages of China’s genetic engineering development
Sales of China’s genetic engineering products 
China’s per capita albumin consumption
China’s GMP blood producers 
Expenses diversions involved in prevention and immunity 
The three vaccines common-used for children in China
Major cancers and death rate caused of cancers in China, 1973-2002 
China’s government input in biotechnology for recent 10 years

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号